Doping Test

*WADA DOPING BANNED SUBSTANCES: * credit https://www.wada-ama.org/en/content/what-is-prohibited

Anabolic agents are prohibited.

1. ANABOLIC ANDROGENIC STEROIDS (AAS)

A. EXOGENOUS * AAS, INCLUDING:

1-androstenediol (5α-androst-1-ene-3β,17β-diol)

1-androstenedione (5α-androst-1-ene-3,17-dione)

1-androsterone (3α-hydroxy-5α-androst-1-ene-17-one)

1-testosterone (17β-hydroxy-5α-androst-1-en-3-one)

Bolasterone

Calusterone

Clostebol

Danazol ([1,2]oxazolo[4',5':2,3]pregna-4-en-20-yn-17α-ol)

Dehydrochlormethyltestosterone (4-chloro-17β-hydroxy-17α-methylandrosta-1,4-dien-3-one)

Desoxymethyltestosterone (17α-methyl-5α-androst-2-en-17β-ol and 17α-methyl-5α-androst-3-en-17β-ol )

Drostanolone

Ethylestrenol (19-norpregna-4-en-17α-ol)

Fluoxymesterone

Formebolone

Furazabol (17α-methyl [1,2,5]oxadiazolo[3',4':2,3]-5α-androstan-17β-ol)

Gestrinone

Mestanolone

Mesterolone

Metandienone (17β-hydroxy-17α-methylandrosta-1,4-dien-3-one)

Metenolone

Methandriol

Methasterone (17β-hydroxy-2α,17α-dimethyl-5α-androstan-3-one)

Methyldienolone (17β-hydroxy-17α-methylestra-4,9-dien-3-one)

Methyl-1-testosterone (17β-hydroxy-17α-methyl-5α-androst-1-en-3-one)

Methylnortestosterone (17β-hydroxy-17α-methylestr-4-en-3-one)

Methyltestosterone

Metribolone (methyltrienolone, 17β-hydroxy-17α-methylestra-4,9,11-trien-3-one)

Mibolerone

Norboletone

Norclostebol

Norethandrolone

Oxabolone

Oxandrolone

Oxymesterone

Oxymetholone

Prostanozol (17β-[(tetrahydropyran-2-yl)oxy]-1'H-pyrazolo[3,4:2,3]-5α-androstane)

Quinbolone

Stanozolol

Stanozolol

Stenbolone

Stenbolone

Tetrahydrogestrinone (17-hydroxy-18a-homo-19-nor-17α-pregna-4,9,11-trien-3-one)

Trenbolone (17β-hydroxyestr-4,9,11-trien-3-one)

and other substances with a similar chemical structure or similar biological effect(s).

B. ENDOGENOUS** AAS AND THEIR METABOLITES AND ISOMERS, WHEN ADMINISTERED EXOGENOUSLY, INCLUDING BUT NOT LIMITED TO:

4-androstenediol (androst-4-ene-3β,17β-diol)

4-hydroxytestosterone (4,17β-dihydroxyandrost-4-en-3-one)

5-androstenedione (androst-5-ene-3,17-dione)

7α-hydroxy-DHEA

7β-hydroxy-DHEA

7-keto-DHEA

19-norandrostenediol (estr-4-ene-3,17-diol)

19-norandrostenedione (estr-4-ene-3,17-dione)

Androstanolone (5α-dihydrotestosterone, 17β-hydroxy-5α-androstan-3-one)

Androstenediol (androst-5-ene-3β,17β-diol)

Androstenedione (androst-4-ene-3,17-dione)

Boldenone

Boldione (androsta-1,4-diene-3,17-dione)

Epiandrosterone (3β-hydroxy-5α-androstan-17-one)

Epi-dihydrotestosterone (17β-hydroxy-5β-androstan-3-one)

Epitestosterone

Nandrolone (19-nortestosterone)

Prasterone (dehydroepiandrosterone, DHEA, 3β-hydroxyandrost-5-en-17-one)

Testosterone

2. OTHER ANABOLIC AGENTS

Including, but not limited to:

Clenbuterol

Selective androgen receptor modulators (SARMs), e.g. andarine, LGD-4033, enobosarm (ostarine) and RAD140;

Tibolone

Zeranol

Zilpaterol

For purposes of this section: 
* “ exogenous” refers to a substance which is not ordinarily produced by the body naturally.
** “ endogenous” refers to a substance which is ordinarily produced by the body naturally.

PEPTIDE HORMONES, GROWTH FACTORS, RELATED SUBSTANCES AND MIMETICS

If a Substance or Method is not defined in this list, please verify with your Anti-Doping Organization.

The following substances, and other substances with similar chemical structure or similar biological effect(s), are prohibited:

1. ERYTHROPOIETINS (EPO) AND AGENTS AFFECTING ERYTHROPOIESIS, INCLUDING, BUT NOT LIMITED TO:

1.1 ERYTHROPOIETIN-RECEPTOR AGONISTS, E.G.

Darbepoetins (dEPO)

Erythropoietins (EPO)

EPO based constructs (EPO-Fc, methoxy polyethylene glycol-epoetin beta (CERA))

EPO-mimetic agents and their constructs , e.g. CNTO-530, peginesatide;

1.2 HYPOXIA-INDUCIBLE FACTOR (HIF) ACTIVATING AGENTS, E.G.

Argon

Cobalt

Daprodustat (GSK1278863)

Molidustat

Roxadustat (FG-4592)

Vadadustat (AKB-6548)

Xenon

1.3 GATA INHIBITORS, E.G.

K-11706

1.4 TGF-BETA (TGF-Β) INHIBITORS, E.G.

Luspatercept

Sotatercept

1.5 INNATE REPAIR RECEPTOR AGONISTS, E.G.

Asialo EPO

Carbamylated EPO (CEPO)

2. PEPTIDE HORMONES AND THEIR RELEASING FACTORS

2.1 CHORIONIC GONADOTROPHIN (CG) AND LUTEINIZING HORMONE (LH) AND THEIR RELEASING FACTORS, IN MALES, E.G.

Buserelin

Deslorelin

Gonadorelin

Goserelin

Leuprorelin

Nafarelin

Triptorelin

2.2 CORTICOTROPHINS AND THEIR RELEASING FACTORS, E.G.

Corticorelin

2.3 GROWTH HORMONE (GH), ITS FRAGMENTS AND RELEASING FACTORS, INCLUDING, BUT NOT LIMITED TO:

Growth Hormone fragments , e.g. AOD-9604 and hGH 176-191;

Growth Hormone Releasing Hormone (GHRH), e.g. CJC-1293, CJC-1295, sermorelin and tesamorelin;

Growth Hormone Secretagogues (GHS), e.g. lenomorelin (ghrelin) and its mimetics, e.g. anamorelin, ipamorelin, macimorelin and tabimorelin;

GH-Releasing Peptides (GHRPs), e.g. alexamorelin, GHRP-1, GHRP-2 (pralmorelin), GHRP-3, GHRP-4, GHRP-5, GHRP-6, and examorelin (hexarelin);

3. GROWTH FACTORS AND GROWTH FACTOR MODULATORS, INCLUDING, BUT NOT LIMITED TO:

Fibroblast Growth Factors (FGFs)

Hepatocyte Growth Factor (HGF)

Insulin-like Growth Factor-1 (IGF-1), and its analogues;

Mechano Growth Factors (MGFs)

Platelet-Derived Growth Factor (PDGF)

Vascular-Endothelial Growth Factor (VEGF)

Thymosin-β4 , and its derivatives e.g. TB-500;


and other growth factors or growth factor modulators affecting muscle, tendon or ligament protein synthesis/degradation, vascularisation, energy utilization, regenerative capacity or fibre type switching.

BETA-2 AGONISTS

If a Substance or Method is not defined in this list, please verify with your Anti-Doping Organization.

All selective and non-selective beta-2 agonists, including all optical isomers, are prohibited;

Including, but not limited to:

Fenoterol

Formoterol

Higenamine

Indacaterol

Olodaterol

Procaterol

Reproterol

Salbutamol

Salmeterol

Terbutaline

Tretoquinol (trimetoquinol)

Tulobuterol

Vilanterol


Except:

  • Inhaled salbutamol: maximum 1600 micrograms over 24 hours;
    in divided doses not to exceed 800 micrograms over 12 hours starting from any dose;
  • Inhaled formoterol: maximum delivered dose of 54 micrograms over 24 hours;
  • Inhaled salmeterol: maximum 200 micrograms over 24 hours.

The presence in urine of salbutamol in excess of 1000 ng/mL or formoterol in excess of 40 ng/mL is not consistent with therapeutic use of the substance and will be considered as an Adverse Analytical Finding (AAF) unless the Athlete proves, through a controlled pharmacokinetic study, that the abnormal result was the consequence of a therapeutic dose (by inhalation) up to the maximum dose indicated above.

HORMONE AND METABOLIC MODULATORS

If a Substance or Method is not defined in this list, please verify with your Anti-Doping Organization.

The following hormone and metabolic modulators are prohibited:

1. Aromatase inhibitors including, but not limited to:

2-Androstenol (5α-androst-2-en-17-ol)

2-Androstenone (5α-androst-2-en-17-one)

3-Androstenol (5α-androst-3-en-17-ol)

3-Androstenone (5α-androst-3-en-17-one)

4-androstene-3,6,17 trione (6-oxo)

Aminoglutethimide

Anastrozole

Androsta-1,4,6-triene-3,17-dione (androstatrienedione)

Androsta-3,5-diene-7,17-dione (arimistane)

Exemestane

Formestane

Letrozole

Testolactone


2. Selective estrogen receptor modulators (SERMs) including, but not limited to:

Raloxifene

Tamoxifen

Toremifene


3. Other anti-estrogenic substances including, but not limited to:

Clomifene

Cyclofenil

Fulvestrant


4. Agents preventing activin receptor IIB activation including, but not limited, to:

Activin A-neutralizing antibodies

Activin receptor IIB competitors (e.g. decoy activin receptors (e.g. ACE-031))

Anti-activin receptor IIB antibodies (bimagrumab)

Myostatin inhibitors (myostatin-neutralizing antibodies (e.g. domagrozumab, landogrozumab, stamulumab), myostatin-binding proteins (e.g. follistatin, myostatin propeptide); agents reducing or ablating myostatin expression)


5. Metabolic modulators:

Activators of the AMP-activated protein kinase (AMPK), eg. AICAR, SR9009;

Peroxisome Proliferator Activated Receptor δ (PPARδ) agonists , e.g. 2-(2-methyl-4-((4-methyl-2-(4-(trifluoromethyl)phenyl)thiazol-5-yl)methylthio)phenoxy) acetic acid (GW1516, GW501516);

Insulins , and insulin-mimetics;

Meldonium

Trimetazidine

DIURETICS AND MASKING AGENTS

If a Substance or Method is not defined in this list, please verify with your Anti-Doping Organization.

The following diuretics and masking agents are prohibited, as are other substances with a similar chemical structure or similar biological effect(s).

Including, but not limited to:

  • Desmopressinprobenecidplasma expanders, e.g. intravenous administration of albumindextranhydroxyethyl starch and mannitol.
  • Acetazolamideamiloridebumetanidecanrenonechlortalidoneetacrynic acidfurosemideindapamidemetolazonespironolactonethiazides, e.g. bendroflumethiazidechlorothiazide and hydrochlorothiazidetriamterene and vaptans, e.g. tolvaptan.

Except:

  • Drospirenone; pamabrom; and ophthalmic use of carbonic anhydrase inhibitors (e.g. dorzolamide, brinzolamide).
  • Local administration of felypressin in dental anaesthesia.

The detection in an Athlete’s Sample at all times or In-Competition, as applicable, of any quantity of the following substances subject to threshold limits: formoterol, salbutamol, cathine, ephedrine, methylephedrine and pseudoephedrine, in conjunction with a diuretic or masking agent, will be considered as an Adverse Analytical Finding (AAF) unless the Athlete has an approved Therapeutic Use Exemption (TUE) for that substance in addition to the one granted for the diuretic or masking agent.

 

Doping Tests1

Doping testing is an activity that is strictly specified in the International Standard for Testing and Investigations. Urine, blood or both are collected as test samples. Doping testing takes place both at competitions and outside of them.

Doping test types

There are two types of doping tests: in-competition tests and out-of-competition tests. An athlete can be summoned to testing at any time and anywhere, either in their home country or abroad. The athlete is invited in person.

In-competition tests

In-competition tests refer to doping tests performed in connection with a competition event. Unless otherwise specified in the rules of the international or another relevant antidoping organisation, this refers to a period starting 12 hours prior to the competition and ending at the end of the competition and the related collection of samples.

All known doping substances and methods and any manipulation of the sample are tested from samples collected in connection with competitions.

The athletes are drawn or ordered to undergo testing based on ranking, for example, or chosen for it as specified in the competition rules of the sport. The athletes can also be ordered to take the test by name in the in-competition tests.

In some sports, a record result (Finnish record, European record, world record) cannot be officially approved until the athlete in question has produced a negative sample. After breaking a record, the athlete must attend the doping control in a manner provided by the rules of the sport. The athlete can acquire further information from his or her sports federation.

Out-of-competition tests

Targeted doping tests are also carried out outside of competitions. Out-of-competition samples are tested for non-approved substances, anabolic agents, peptide hormones, growth factors and similar substances, ß2-agonists, hormone and metabolism modulators, diuretics and other masking agents as well as all prohibited methods.

International sports federations may have rules of their own regarding the substances to be tested. It is the athletes responsibility to be aware of the relevant rules.

Athletes are chosen for out-of-competition tests in a targeted manner or by drawing the athletes to be tested during the training of a certain group or athletes on a camp. In targeted tests, FINADA or another antidoping organisation that has ordered the test has named the athlete in advance for the test.

Targeted tests are mainly carried out for testing pool and national team athletes. FINADA can, however, target any athlete bound by the antidoping code for testing, both in-competition and out-of-competition.

Out-of-competition tests also include follow-up tests made to clarify the results of previous tests and tests carried out during a period of ineligibility due to antidoping rule violations.